Abramson Cancer Center Support Grant

Abramson癌症中心 宾夕法尼亚大学的艾布拉姆森癌症中心（ACC）是最古老的NCI指定癌症中心之一。 综合癌症中心。ACC服务于一个种族和经济多样化的集水区- 12 宾夕法尼亚州、新泽西州和特拉华州的相邻县，约有700万居民。 我们集水区的居民面临的癌症发病率明显高于该国其他地区。 通过综合，动态和高影响力的研究计划，追求基础，临床和人口- 基于研究，ACC促进开拓性的科学发现，并促进这些发现的翻译 将新发现转化为临床实践，转变以患者为中心的癌症护理和癌症控制的范式。 ACC在三家宾州医学成人医院和宾夕法尼亚州儿童医院提供非凡的癌症护理。 费城ACC通过成为大学强大的学术生态系统的一部分而得到进一步加强 宾夕法尼亚州。ACC的使命是减少整个集水区的癌症负担， 通过独特的综合性，生产性和全面的研究工作，国家和世界。我们的愿景 是建立一个特殊的科学驱动，以病人为中心的综合性癌症中心， 持久的影响。ACC拥有324名成员，9个研究项目，9个共享资源，以及强大的 社区外展和参与团队、临床方案和数据管理团队、方案审查团队 和监测系统，癌症研究培训和教育，以及管理。在目前的资金 在此期间，ACC成员发表了4，052篇手稿，并招募了22，000多名受试者进行干预 超过37，000名受试者参与了非干预性试验。ACC成员每年直接持有1.701亿美元 其中1.032亿美元来自NIH，5920万美元来自NCI。ACC成员持有267 R 01- 等价物ACC的显着优势包括非凡的智力资本，独特的协作 推动转化研究的文化，平衡而强大的研究组合，对我们的 集水区，和一个现代化的和不断扩大的癌症临床企业，为成人和儿童的护理。 本资助期内的主要成就包括免疫学、细胞免疫学和细胞免疫学的变革性科学。 生物学、生殖系遗传学和表观遗传学;影响范围从实验室到旁边的临床试验 到多个FDA批准，包括开发，翻译和FDA批准CAR T细胞作为第一个 癌症基因治疗;质子辐射和分子成像的新方法; 戒烟和HPV疫苗接种;黑人受试者参与临床试验的人数增加一倍;以及 领导推动围绕吸烟和含糖饮料的新健康政策。通过利用新的机构， 慈善和其他资源，ACC继续创新，以减少我们国家的癌症负担， 集水区及其他地区，坚持不懈地以全面和严格的方式改善生活 癌症患者和有风险的人。

PROJECT SUMMARY – Abramson Cancer Center The Abramson Cancer Center (ACC) at the University of Pennsylvania is one of the oldest NCI-Designated Comprehensive Cancer Centers. The ACC serves an ethnically and economically diverse catchment area – 12 contiguous counties in Pennsylvania, New Jersey, and Delaware, with approximately 7 million residents. Residents in our catchment area face significantly higher rates of cancer incidence than the rest of the country. Through integrated, dynamic, and high-impact Research Programs pursuing basic, clinical, and population- based research, the ACC fosters pioneering scientific discoveries and facilitates the translation of these discoveries into clinical practice, transforming paradigms of patient-centered cancer care and cancer control. ACC provides extraordinary cancer care at three Penn Medicine adult hospitals and Children's Hospital of Philadelphia. The ACC is further enhanced by being part of the powerful academic ecosystem of the University of Pennsylvania. The ACC mission is to reduce the burden of cancer throughout our catchment area, the nation, and the world through uniquely integrated, productive, and comprehensive research efforts. Our vision is to exemplify an exceptional science-driven, patient-focused comprehensive cancer center with deep and lasting impact. The ACC has 324 members, nine Research Programs, nine Shared Resources, and robust teams for Community Outreach and Engagement, Clinical Protocol and Data Management, Protocol Review and Monitoring Systems, Cancer Research Training and Education, and Administration. In the current funding period, ACC members published 4,052 manuscripts and enrolled more than 22,000 subjects on interventional trials and more than 37,000 subjects on non-interventional trials. ACC members hold $170.1M in annual direct funds, of which $103.2M comes from the NIH and $59.2M from the NCI. ACC members hold 267 R01- equivalents. Notable strengths of the ACC include extraordinary intellectual capital, a uniquely collaborative culture that drives translational research, a balanced and strong research portfolio, deep commitment to our catchment area, and a modern and expanding cancer clinical enterprise for the care of adults and children. Chief accomplishments in the current funding period include transformative science in immunology, cell biology, germline genetics, and epigenetics; clinical trials with impact ranging from bench-to-beside discovery to multiple FDA approvals, including development, translation, and FDA approval of CAR T cells as the first cancer gene therapy; novel approaches in proton radiation and molecular imaging; nation-leading efforts in smoking cessation and HPV vaccination; doubling of Black subjects' participation in clinical trials; and leadership driving new health policy around smoking and sugary beverages. By leveraging new Institutional, philanthropic, and other resources, the ACC continues to innovate to reduce the burden of cancer in our catchment area and beyond, relentlessly working in a comprehensive and rigorous fashion to improve the lives of cancer patients and those at risk.